Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 5, 2014, Pages 417-425

  Yoon, Alyssa H ^a   Ye, Yumei ^b   Birnbaum, Yochai ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase inhibitors; Glucagon like peptide 1; Infarct; Ischemia reperfusion

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; GENE INACTIVATION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MOUSE MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT MODEL; REPERFUSION INJURY; REVIEW; ANIMAL; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE MODEL; MYOCARDIAL REPERFUSION INJURY; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; MYOCARDIAL REPERFUSION INJURY; RISK FACTORS;

EID: 84928169199     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414524482     Document Type: Review

References (40)

1. World Health Organization. 10 facts about diabetes; 2013. http://www.who.int/features/factfiles/diabetes/en/index.html. Reviewed October 2013. Accessed November 1, 2013.
2. Centers for Disease Control and Prevention (CDC). National estimates and general information on diabetes and prediabetes in the United States, 2011. In: U.S. Department of Health and Human Services, ed. National Diabetes Fact Sheet. Atlanta, GA: Centers for Disease Control and Prevention; 2011.
3. Stratton IM AA, Neil AW, Mattews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br J Med. 2000;321(7258):405-412.
4. The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011; 362(9):818-828.
5. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
6. Solun B, Marcoviciu D, Dicker D. Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system. Curr Cardiol Rep. 2013;15(8):382.
7. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol. 2013;10(2):73-84.
8. Papazafiropoulou A, Pappas SI, Papadogiannis D, Tentolouris N. Cardiovascular effects of glucagon-like peptide 1. Mini Rev Med Chem. 2011;11(1):97-105.
9. Balakumar P, Dhanaraj SA. Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials. Cell Signal. 2013;25(9): 1799-1803.
10. Birnbaum Y, Castillo AC, Qian J, et al. Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012;26(6):445-456.
11. Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia- reperfusion injury. Basic Res Cardiol. 2011;106(6):925-952.
12. Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5(2):288-295.
13. Woo JS, KimW, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol. 2013;33(9):2252-2260.
14. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010;298(5):H1454-H1465.
15. Theiss HD, Gross L, Vallaster M, et al. Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction. Int J Cardiol. 2013; 168(4):3359-3369.
16. Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol. 2013;167(2):451-457.
17. Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010;59(4):1063-1073.
18. Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, prediabetic rats. Cardiovasc Drugs Ther. 2011;25(1):13-20.
19. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol. 2005;45(8): 1287-1291.
20. Chinda K, Chattipakorn S, Chattipakorn N. Cardioprotective effects of incretin during ischaemia-reperfusion. Diab Vasc Dis Res. 2012;9(4):256-269.
21. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124-1136.
22. Dai Y, Dai D, Mercanti F, Ding Z, Wang X, Mehta JL. Dipeptidyl peptidase-4 inhibitors in cardioprotection: A promising therapeutic approach. Acta Diabetol. 2013;50(6):827-835. doi:10.1007/s00592-013-0496-4.
23. Yin M, Westenbrink BD, Meissner M, van Gilst WH, de Boer RA. Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist. Int J Cardiol. 2013;169(6):385-393.
24. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1. Vascul Pharmacol. 2011;55(1-3):10-16.
25. Wang XM, Yang YJ, Wu YJ. The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives. Cardiovasc Drugs Ther. 2013; 27(4):297-307.
26. Chaudhuri A, Ghanim H, Vora M, et al Exenatide exerts a potent anti-inflammatory effect. J Clin Endocrinol Metab. 2012;97(1): 198-207.
27. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340-2350.
28. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010;33(7): 1607-1609.
29. Lunder M, Ziberna L, Janic M, et al. Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta. Heart Vessels. 2013; 28(2):246-254.
30. Prakash P, Khanna V, Singh V, et al. Atorvastatin protects against ischemia-reperfusion injury in fructose-induced insulin resistant rats. Cardiovasc Drugs Ther. 2011;25(4):285-297.
31. Lardizabal JA, Deedwania PC. The anti-ischemic and anti-anginal properties of statins. Curr Atheroscler Rep. 2011;13(1):43-50.
32. Hausenloy DJ, Baxter G, Bell R, et al. Translating novel strategies for cardioprotection: The Hatter workshop recommendations. Basic Res Cardiol. 2010;105(6):677-686.
33. Ovize M, Baxter GF, Di Lisa F, et al. Postconditioning and protection from reperfusion injury: Where do we stand? Position paper from the working group of cellular biology of the heart of the European society of cardiology. Cardiovasc Res. 2010; 87(3):406-423.
34. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl JMed. 2013;369(14):1327-1335.
35. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326.
36. Rosenstock J, Marx N, Kahn SE, et al. Rationale and Design of the CAROLINA Trial: An Active Comparator CARdiOvascular Outcome Study of theDPP-4 InhibitorLINAgliptin inPatientsWithType 2 Diabetes at High Cardiovascular Risk [Poster]. San Diego, CA: 71st Scientific Sessions of American Diabetes Association; 2011.
37. Bethel MA Green J, Califf RM, Holman RR. Rational and design of the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes. 2009;58(suppl 1):A639.
38. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for reduction of myocardial damage during angioplasty) randomized trial. J Am Coll Cardiol. 2009;54(6):558-565.
39. Parlakpinar H, Ozer MK, Acet A. Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size. Cytokine. 2011; 56(3):688-694.
40. Mohanty IR, Arya DS, Dinda A, Gupta SK. Comparative cardioprotective effects and mechanisms of vitamin E and lisinopril against ischemic reperfusion induced cardiac toxicity. Environ Toxicol Pharmacol. 2013;35(2):207-217.